

A New Chapter in ROIS Commercial Leadership. Meet Kimberlee Steele.

ROIS today announced the appointment of Kimberlee Steele as Chief Commercial Officer, effective from 1 March 2026. Kimberlee will spearhead global commercial strategy at ROIS, overseeing business development, marketing and strategic partnerships to support the company's continued growth as a leading global sterile CDMO.

"Kimberlee's extensive industry experience, commercial acumen and deep understanding of complex drug product and delivery technologies make her an outstanding addition to the ROIS leadership team," said CEO Javier López-Belmonte.

"Her appointment reinforces our commitment to delivering high quality sterile CDMO solutions to our global customers as we continue to expand our capabilities in Europe and the United States."

Kimberlee said: "I am honoured to take on this role at such a pivotal time, as the company expands its presence in the United States through the acquisition and growth of a new sterile fill/finish site in Phoenix, Arizona, further strengthening its position as a truly global CDMO."

Kimberlee brings more than 25 years of experience across the pharmaceutical, medical device, consulting and technology sectors. She has deep expertise in commercial leadership, strategic partnerships, and end to end drug product and drug delivery technologies, with a track record of driving growth in complex, global organisations.

ROIS has developed an exceptional sterile CDMO platform: its annual fill/finish capacity of over 750 million units of prefilled syringes, cartridges and vials places it in the global top three. As an injectables CDMO, ROIS delivers comprehensive end-to-end services, encompassing manufacturing, packaging and assembly – including integration with AI and PEN devices.



A seasoned life sciences executive, **Kimberlee Steele** brings more than 25 years of experience across pharmaceutical manufacturing and CDMO services to ROIS. Recently serving as Managing Director, North America at SHL Medical, Kimberlee owned full P&L responsibility for final assembly and packaging operations, and supported a 300,000 square foot expansion to establish US-based autoinjector manufacturing in South Carolina. Previously, Kimberlee spent 12 years at Catalent Pharma Solutions, advancing to Vice President of Strategic Partners, supporting growth across biologics, injectables, cell and gene therapy, and advanced drug delivery technologies. She is also a long-standing DCAT member.

[Click Here to read more about our new CCO Kimberlee.](#)

